

<p style="text-align: center;"><b>KABRA DRUGS LIMITED</b>  CIN:- L02423MP1989PLC005438  Regd Off: 208 Swadesh Bhavan, 2 Press Complex, AB Road, R.S.S.Nagar, Indore, Madhya Pradesh, India, 452011</p>					
(Rs. In lacs)					
Statement of Un-audited Standalone Financial Results for the Quarter Ended June 30, 2025					
Sl no.	Particulars	Quarter Ended			Year Ended
		30-Jun-25	31-Mar-25	30-Jun-24	31-Mar-25
	(Refer Notes Below)	(Unaudited)	(Audited)	(Unaudited)	(Audited)
	<b>INCOME</b>				
(a)	Revenue from Operations	715.00	-	-	-
(b)	Other Income	1.62	64.02	-	64.02
<b>1</b>	<b>Total Income</b>	<b>716.62</b>	<b>64.02</b>	<b>-</b>	<b>64.02</b>
	<b>EXPENSES</b>				
(a)	Cost of materials consumed	-	-	-	-
(b)	Purchases of Stock-in-Trade	675.00	-	-	-
(c)	Changes in inventories of finished goods, work-in-progress, and stock-in-trade	-	-	-	-
(d)	Employee benefit expense	37.81	25.13	10.59	69.23
(e)	Finance Costs	-	-	-	-
(f)	Depreciation and amortization expense	0.34	0.55	-	0.73
(g)	Other expenses	53.46	(0.93)	43.97	102.56
<b>2</b>	<b>Total Expenses</b>	<b>766.60</b>	<b>24.75</b>	<b>54.57</b>	<b>172.53</b>
<b>3</b>	<b>Profit / (Loss) from operations before exceptional items Tax (1-2)</b>	<b>(49.98)</b>	<b>39.26</b>	<b>(54.57)</b>	<b>(108.51)</b>
<b>4</b>	<b>Exceptional Items</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
<b>5</b>	<b>Profit / (Loss) before Tax (3 ± 4)</b>	<b>(49.98)</b>	<b>39.26</b>	<b>(54.57)</b>	<b>(108.51)</b>
<b>6</b>	<b>Tax Expense</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
(a)	Current Tax				
(b)	Deferred Tax	(0.00)	(0.10)		0.05
(c)	Earlier Year Tax				
(d)	MAT Credit entitlement				
	<b>Total Tax Expenses</b>	<b>(0.00)</b>	<b>(0.10)</b>	<b>-</b>	<b>0.05</b>
<b>7</b>	<b>Net Profit / (Loss) after Tax (5 - 6)</b>	<b>(49.98)</b>	<b>39.36</b>	<b>(54.57)</b>	<b>(108.56)</b>
<b>8</b>	<b>Other Comprehensive Income (net of tax )</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>-</b>
A	(i) Items that will not be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will not be reclassified to profit or loss	-	-	-	-
B	(i) Items that will be reclassified to profit or loss	-	-	-	-
	(ii) Income tax relating to items that will be reclassified to profit or loss	-	-	-	-
<b>9</b>	<b>Total Comprehensive Income for the period (7 ± 8)</b>	<b>(49.98)</b>	<b>39.36</b>	<b>(54.57)</b>	<b>(108.56)</b>
<b>10</b>	<b>Paid-up equity share capital (Face Value of Rs.10/- each)</b>	<b>2,370.79</b>	<b>2,370.79</b>	<b>438.86</b>	<b>2,370.79</b>
<b>11</b>	<b>Other Equity</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>94.68</b>
<b>12</b>	<b>Earnings Per Share (of Rs. 10/- each) (not annualised):</b>				
(a)	Basic	(0.21)	0.21	(1.24)	(0.99)
(b)	Diluted	(0.21)	0.21	(1.24)	(0.99)
<b>Notes:</b> <p>The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at its meeting held on August 14, 2025. The Statutory Auditors have carried out a limited review of the above financial result.</p> <p>1 Company has only one segment and hence no separate segment result has been given.</p> <p>2 The figure of previous period/year have been re-grouped / re-arranged and /or recast wherever found necessary.</p> <p>3 This statement is as per Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015</p>					
<b>For and on Behalf of the Board of directors of</b> <b>For, Kabra Drugs Ltd</b>					
<b>Nanjappan Aravind</b> Managing Director DIN: 01895602					
<b>Place : Indore</b> <b>Date : 14-08-2025</b>					